Acetylsalicylic acid/dipyridamole
 | |
| Combination of | |
|---|---|
| Acetylsalicylic acid | Antithrombotic |
| Dipyridamole | Antithrombotic |
| Clinical data | |
| Trade names | Aggrenox, Asasantin |
| AHFS/Drugs.com | UK Drug Information |
| Routes of administration | Oral |
| Identifiers | |
| CAS Number | 87653-67-6 |
| ATC code | B01AC30 (WHO) |
| PubChem | CID 137329 |
| ChemSpider | 121018 |
The combination drug acetylsalicylic acid/dipyridamole (trade names Aggrenox, Asasantin) is a drug combination of:[1]
- Acetylsalicylic acid, the analgesic otherwise (but in higher doses) trademarked as Aspirin
- Dipyridamole, a drug that inhibits thrombus formation[2] when given chronically and causes vasodilation when given at high doses over short time.
The combination acts as an extended release formulation and is primarily used for platelet inhibition in patients suffering, or at risk from, acute coronary events such as stroke.[3] Its use has been shown to be better than the use of either dipyridamole or aspirin alone.[4]
References
- ↑ FASS (the Swedish official drug catalog) > Asasantin Last update: 2009–08–17
- ↑ "Dipyridamole" at Dorland's Medical Dictionary
- ↑ Malinin, Alex I.; Eisert, Roswith M.; Atar, Dan; Barkagan, Zinoviy; Serebruany, Victor L. (2002). "Aggrenox® (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events". Heart Drug 2 (2): 93–104. doi:10.1159/000063427.
- ↑ Serebruany, Victor L.; Malinin, Alex I.; Sane, David C.; Jilma, Bernd; Takserman, Aviv; Atar, Dan; Hennekens, Charles H. (September 2004). "Magnitude and time course of platelet inhibition with Aggrenox® and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial". European Journal of Pharmacology 499 (3): 315–324. doi:10.1016/j.ejphar.2004.07.114.
| ||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.